title: [Investigation of possible approaches to angiogenesis regulation in vitro with the help of recombinant fragments of angiogenesis inhibitors such as endostatin, tumstatin and PEDF].
abstract: Neovascular diseases of visual organ such as age-related macular degeneration, retinopathy of prematurity, diabetic retinopathy, thrombosis of central retina vein and its branches, neovascular glaucoma, choroid and retina tumors have the leading positions in the list of ophtalmopatologies that result in blindness and incapacity. The variety of angiostatic medications of applied ophtalmology is scant. The aim of work was to study the possibile approaches to angiogenesis regulation in vitro with the help of recombinant fragments of natural inhibitors of angiogenesis such as endostatin, tumstatin and PEDF (pigment epithelial derived factor), and also theirability to be the base of potentially feasible and pharmacologically active substances. It is determined that endostatin, tumstatin and PEDF, as well as the comparison medication Bevacizumab in vitro have pro-or antiangiogenic influence. The direction of the biological effect depends on the cultivation conditions, peptide concentration in the cultural fluid and stage of angiogenesis.
authors.forename: S L
authors.initials: SL
authors.lastname: Kuznetsov
authors.forename: V G
authors.initials: VG
authors.lastname: Likhvantseva
authors.forename: E V
authors.initials: EV
authors.lastname: Arutiunian
authors.forename: K A
authors.initials: KA
authors.lastname: Kuz'min
authors.forename: S A
authors.initials: SA
authors.lastname: Sel'kov
authors.forename: D I
authors.initials: DI
authors.lastname: Sokolov
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001324:Autoantigens / Q000627:therapeutic use*; D002478:Cells, Cultured; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D024141:Collagen Type IV / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000473:pathology; D043169:Endostatins / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology; D000939:Epitopes; D005136:Eye Proteins / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D015843:Serpins / Q000627:therapeutic use*; D016896:Treatment Outcome; D000099174:Pigment Epithelium-Derived Factor
chemical_list: D020533:Angiogenesis Inhibitors; D001324:Autoantigens; D024141:Collagen Type IV; D043169:Endostatins; D000939:Epitopes; D005136:Eye Proteins; D009414:Nerve Growth Factors; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D015843:Serpins; D000099174:Pigment Epithelium-Derived Factor; C057112:type IV collagen alpha3 chain